Literature DB >> 21285522

Energy deficit in Huntington disease: why it matters.

Fanny Mochel1, Ronald G Haller.   

Abstract

Huntington disease (HD) is an autosomal dominant neurodegenerative disease with complete penetrance. Although the understanding of the cellular mechanisms that drive neurodegeneration in HD and account for the characteristic pattern of neuronal vulnerability is incomplete, defects in energy metabolism, particularly mitochondrial function, represent a common thread in studies of HD pathogenesis in humans and animal models. Here we review the clinical, biochemical, and molecular evidence of an energy deficit in HD and discuss the mechanisms underlying mitochondrial and related alterations.

Entities:  

Mesh:

Year:  2011        PMID: 21285522      PMCID: PMC3026743          DOI: 10.1172/JCI45691

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  122 in total

1.  Biochemical abnormalities and excitotoxicity in Huntington's disease brain.

Authors:  S J Tabrizi; M W Cleeter; J Xuereb; J W Taanman; J M Cooper; A H Schapira
Journal:  Ann Neurol       Date:  1999-01       Impact factor: 10.422

2.  1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers.

Authors:  B G Jenkins; H D Rosas; Y C Chen; T Makabe; R Myers; M MacDonald; B R Rosen; M F Beal; W J Koroshetz
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

3.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

4.  Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy.

Authors:  R Lodi; A H Schapira; D Manners; P Styles; N W Wood; D J Taylor; T T Warner
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

5.  Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates.

Authors:  Hirokazu Fukui; Carlos T Moraes
Journal:  Hum Mol Genet       Date:  2007-03-13       Impact factor: 6.150

6.  Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis.

Authors:  Juliette D Godin; Kelly Colombo; Maria Molina-Calavita; Guy Keryer; Diana Zala; Bénédicte C Charrin; Paula Dietrich; Marie-Laure Volvert; François Guillemot; Ioannis Dragatsis; Yohanns Bellaiche; Frédéric Saudou; Laurent Nguyen; Sandrine Humbert
Journal:  Neuron       Date:  2010-08-12       Impact factor: 17.173

7.  Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain.

Authors:  E O'Gorman; G Beutner; T Wallimann; D Brdiczka
Journal:  Biochim Biophys Acta       Date:  1996-09-12

8.  A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease.

Authors:  Claus Zabel; Lei Mao; Ben Woodman; Michael Rohe; Maik A Wacker; Yvonne Kläre; Andrea Koppelstätter; Grit Nebrich; Oliver Klein; Susanne Grams; Andrew Strand; Ruth Luthi-Carter; Daniela Hartl; Joachim Klose; Gillian P Bates
Journal:  Mol Cell Proteomics       Date:  2008-11-30       Impact factor: 5.911

9.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

10.  Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.

Authors:  Diane T W Chang; Gordon L Rintoul; Sruthi Pandipati; Ian J Reynolds
Journal:  Neurobiol Dis       Date:  2006-02-09       Impact factor: 5.996

View more
  78 in total

1.  Sodium selenite protects from 3-nitropropionic acid-induced oxidative stress in cultured primary cortical neurons.

Authors:  Dirleise Colle; Danúbia Bonfanti Santos; Viviane de Souza; Mark William Lopes; Rodrigo Bainy Leal; Patricia de Souza Brocardo; Marcelo Farina
Journal:  Mol Biol Rep       Date:  2018-12-03       Impact factor: 2.316

2.  pH as a biomarker of neurodegeneration in Huntington's disease: a translational rodent-human MRS study.

Authors:  Myriam M Chaumeil; Julien Valette; Céline Baligand; Emmanuel Brouillet; Philippe Hantraye; Gilles Bloch; Véronique Gaura; Amandine Rialland; Pierre Krystkowiak; Christophe Verny; Philippe Damier; Philippe Remy; Anne-Catherine Bachoud-Levi; Pierre Carlier; Vincent Lebon
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-29       Impact factor: 6.200

Review 3.  The search for sensitive biomarkers in presymptomatic Huntington disease.

Authors:  Pierre-Gilles Henry; Fanny Mochel
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-29       Impact factor: 6.200

4.  trans-(-)-ε-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington Disease.

Authors:  Jinrong Fu; Jing Jin; Robert H Cichewicz; Serena A Hageman; Trevor K Ellis; Lan Xiang; Qi Peng; Mali Jiang; Nicolas Arbez; Katelyn Hotaling; Christopher A Ross; Wenzhen Duan
Journal:  J Biol Chem       Date:  2012-05-30       Impact factor: 5.157

5.  Metabolic Reprogramming in Astrocytes Distinguishes Region-Specific Neuronal Susceptibility in Huntington Mice.

Authors:  Aris A Polyzos; Do Yup Lee; Rupsa Datta; Meghan Hauser; Helen Budworth; Amy Holt; Stephanie Mihalik; Pike Goldschmidt; Ken Frankel; Kelly Trego; Michael J Bennett; Jerry Vockley; Ke Xu; Enrico Gratton; Cynthia T McMurray
Journal:  Cell Metab       Date:  2019-03-28       Impact factor: 27.287

Review 6.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

7.  Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.

Authors:  Karen Marder; Yian Gu; Shirley Eberly; Caroline M Tanner; Nikolaos Scarmeas; David Oakes; Ira Shoulson
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

Review 8.  The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease.

Authors:  Aris A Polyzos; Cynthia T McMurray
Journal:  Mech Ageing Dev       Date:  2016-09-12       Impact factor: 5.432

9.  Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions.

Authors:  Lydie Boussicault; Anne-Sophie Hérard; Noel Calingasan; Fanny Petit; Carole Malgorn; Nicolas Merienne; Caroline Jan; Marie-Claude Gaillard; Rodrigo Lerchundi; Luis F Barros; Carole Escartin; Thierry Delzescaux; Jean Mariani; Philippe Hantraye; M Flint Beal; Emmanuel Brouillet; Céline Véga; Gilles Bonvento
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-18       Impact factor: 6.200

Review 10.  Does PGC1α/FNDC5/BDNF Elicit the Beneficial Effects of Exercise on Neurodegenerative Disorders?

Authors:  Mohammad Jodeiri Farshbaf; Kamran Ghaedi; Timothy L Megraw; Jennifer Curtiss; Mahsa Shirani Faradonbeh; Pooneh Vaziri; Mohammad Hossein Nasr-Esfahani
Journal:  Neuromolecular Med       Date:  2015-11-26       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.